Myriad Genetics
MYGN
221 hedge funds and large institutions have $568M invested in Myriad Genetics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 85 increasing their positions, 75 reducing their positions, and 26 closing their positions.
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
13% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 75
3.82% more ownership
Funds ownership: 95.13% → 98.94% (+3.8%)
0% more funds holding
Funds holding: 221 → 221 (0)
11% less capital invested
Capital invested by funds: $640M → $568M (-$71.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$14.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.18M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$4.52M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$3.38M |
| 5 |
BlackRock
New York
|
+$3.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Algert Global
San Francisco,
California
|
-$3.97M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$3.65M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.96M |
| 4 |
HF
HRT Financial
New York
|
-$2.33M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$2.27M |
MYGN Hedge Fund Activity: Q4 2025 in Review
221 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2025, worth a combined $568M — down 11% from $640M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new MYGN positions and 26 closed out — a net gain of 5 holders — while 85 added to existing stakes and 75 trimmed.
The largest buyer was Millennium Management, adding an estimated $14.2M. The largest seller was Algert Global, cutting an estimated $3.97M.
- 221 institutional investors held Myriad Genetics (MYGN) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $568M of Myriad Genetics stock for Q4 2025, down 11% quarter-over-quarter.
- 31 funds opened new Myriad Genetics positions in Q4 2025 and 26 closed out, a net change of +5 holders.
- The largest Myriad Genetics buyer in Q4 2025 was Millennium Management, an estimated $14.2M added.
- The largest Myriad Genetics seller in Q4 2025 was Algert Global, an estimated $3.97M sold.
Based on aggregated 13F filings for Q4 2025.